

North Central Cancer Treatment Group

N0572: A Phase I/II Study of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma

Status Change – May 21, 2008

**NOTICE OF STATUS CHANGE**

The Phase II dose has been reduced per section 7.21. The Phase II dose level, as referenced in section 7.22 and 7.23, has been reduced to dose level -1 (Sorafenib dose 200mg bid, CCI-779 dose 20mg) shown in the table in section 7.12 for 3 patients effective Wednesday, May 21, 2008.

**Please retain this notice with the protocol.**